Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen British Medical Journal, 1977, 2, 487-490 Summary The frequency of menstruation was reduced to once every three months in 196 women by the continuous administration of the oral contraceptive pill, Minilyn, for 84 days (tri-cycle regimen). No pregnancies occurred. One hundred and sixty-one women (82%) welcomed the reduction in the number of periods with the as- EHl 2QW A L GUILD, MA, research technician R V SHORT, SCD, FRS, director sociated freedom from menstrual and premenstrual symptoms, and many. found the tri-cycle regimen easier to follow. Weight gain -of more than 2 kg, irregular cycle control, especially in the -first three months, breast tenderness, and. headaches were the main side effects. Menstrual loss was unchanged or reduced in all but seven women. The doctors and nurses on the clinic staff were less-enthusiastic about this regimen than the volunteers themselves.
reasonable to assume that Paget's disease was a major contributing factor to deafness in most of these cases.
Audiological assessment was confined to a clinical examination, and pure-tone and impedance audiometry. Tone decay and tests for recruitment and speech audiometry were not included because they do not clarify the diagnosis and they would have been confusing and tiring for a group of elderly patients. Temporal bone tomography was not undertaken because of the risks to the eye.
With these tests we have observed a trend for the conductive component and to a lesser degree the high-frequency sensorineural component of deafness to deteriorate less rapidly in patients on continuous calcitonin treatment than in untreated patients. Intermittently treated patients showed intermediate changes. The observations in case 7 suggest that hearing loss may be delayed though not actually prevented by effective calcitonin treatment.
Previous reports of the effect of calcitonin on deafness have shown conflicting results. Shai et alU reported an improvement in air conduction at low frequencies in three out of six patients treated with porcine calcitonin for six to 17 weeks. Moffat et al9 reported a single case of improvement after 23 weeks' porcine calcitonin treatment. Neither of these studies included a control group and the patient described by Moffat et al had no evidence of Paget's disease in the skull. Grimaldi et al'O failed to show any change in the hearing of their patients who were treated with salmon or human calcitonin for 12 to 62 weeks, nor could Menzies et all' show any improvement in the hearing of four patients treated with human calcitonin' " I after 18-22 months. In general the severity of deafness in Paget's disease is related to the extent of the bony disease, and most suggested mechanisms are related to the abnormal bone architecture. If long-term calcitonin treatment is effective in arresting the disease process or even in restoring bone structure to a more normal state then some benefit to hearing might be expected to occur, and our results suggest that this may indeed be so. Nevertheless, the number of patients, the period of observation, and the size of the changes are small. On the available evidence, deafness should not be regarded as an indication for calcitonin therapy in Paget's disease, but our findings suggest that further moreprolonged studies are needed.
Introduction
When Dr Gregory Pincus first developed the oral contraceptive pill in the late 1950s he proposed a dosage regimen that would induce withdrawal bleeding every 28 days. Although the length of the cycle while on the pill is purely arbitrary, Pincus tried to imitate as closely as possible the length of the normal menstrual cycle to make the pill more acceptable when oral contraception was still a novel concept.
Since then the ability of synthetic ovarian hormones to control ovulation has been widely exploited, and it is now estimated that over 50 million women use the pill'; probably days followed by 6 pill-free days to allow for withdrawal bleeding. Patients who were not already taking oral contraceptives began the tri-cycle regimen on the first day of menstruation, and contraceptive cover was considered to be effective immediately. Patients who transferred from the normal pill-taking regimen did so after the standard interval of six or seven pill-free days. Additional contraceptive precautions were recommended for the first 14 days after the changeover. The tri-cycle regimen was continued for one year, giving four withdrawal bleeds at three-monthly intervals.
Each woman kept a diary card to record tablet-taking, uterine bleeding, and any side effects she chose to specify. After completing 12 months on the tri-cycle pill, or after premature withdrawal from the trial, each woman was invited to complete a simple written questionnaire. The first two questions invited the woman's free comments on general likes and dislikes about the tri-cycle regimen. These were followed by four specific questions on whether or not she had been concerned about the risk of pregnancy; the possibility that her periods might not return; whether the regimen was "interfering with nature" in a way that was not fully understood; and whether she would feel happier with monthly cycles because they were more "natural."
Women who failed to keep their clinic appointments were followed up by letter or by home visit. Permission to follow up in this way had been obtained at enrolment.
Results
The age distribution, marital state, and social class of the volunteers appeared to reflect the general clinic population, and was biased towards social classes I, II, and III. Of the 202 women who enrolled in the trial, six were lost to follow-up within the first three months, submitting no data, and not completing the questionnaire. One hundred and seven women completed the whole 12 months, and 89 withdrew (table I). Fourteen of the women who withdrew did so either to plan a pregnancy, for sterilisation, or because contraception BRITISH MEDICAL JOURNAL 20 AUGUST 1977 was no longer required (table II) . Of the nine women who stopped to plan a pregnancy, six are known to have conceived within nine months, while two were still not pregnant after 10 and 11 months, and one was lost to follow-up. The two who failed to become pregnant had used Minilyn tri-cyclically for six and three months respectively. An appointment was made for one patient to attend the endocrine clinic, but she failed to attend, and subsequently left the area. The other was referred to the infertility clinic and her husband was being investigated for Klinefelter's syndrome. ) reported a decline), but the relevance of this was difficult to assess. In response to four specific questions some women, even though giving overall approval to the regimen, had reservations about certain aspects of it. Forty-five (230%) were concemed by the lack of the monthly menstrual reassurance that they were not pregnant, but this doubt diminished with successive three-monthly cycles. Sixteen (8 %) worried 489 that their periods might not return when they stopped the tri-cycle regimen, and 51 (260%) were genuinely worried that they were interfering with nature in a way which they did not understand.
Thirty-seven (19 0%) admitted at the end of their participation in the trial that they were happier with monthly cycles, but even among those who discontinued the trial for one reason or another, 41 (46%) said that they would be willing to try the tri-cycle regimen at a future date using a lower dose pill. At the end of the trial, all those still taking part were asked to revert to the standard monthly oral contraceptive regimen; 97 (91 0%) refused to do this, preferring to continue with tri-cycle Minilyn. Sixteen (15 %) even declined an offer to transfer to a tri-cycle pill containing a lower dose of oestrogen.
PERCEPTIONS OF CLINIC STAFF
All the doctors and nurses working in the family planning centre took part in running this trial. On completion of the trial the 24 doctors and 9 nurses were asked to complete a questionnaire. Seventeen (520%) of the staff approved to the idea of reduction in number of periods, and 14 (42 %) were impressed by the diminution in adverse menstrual symptoms reported by patients. Seven (21 %) found that the tri-cycle pill regimen was easier for patients to follow, and six (18 %) stated that the reduction in cost to the patient of sanitary protection was an important consideration.
Nevertheless, 13 (39 %) were concemed that patients might become pregnant without the medical adviser knowing about it, although a doctor resorted to a pregnancy test only once to allay this fear.
Seven (21 %) were worried by weight increase, and six (180%) considered irregular vaginal bleeding to be a source of concern. Four (12 %) were disturbed by increased breast tenderness, and four (12 %) also disapproved of manipulation of the menstrual cycle to reduce the number of periods. Ten (30 %) expressed concern lest regular monthly menstruation could not be re-established when tri-cycle pill treatment was discontinued.
Half of the doctors preferred to prescribe the pill according to the routine monthly regimen. Only one member of staff, a nurse, was unwilling to participate in another trial using a lower dose of oestrogen in a tri-cycle pill.
Discussion
This study shows unequivocally that many of the women who volunteered to take part in this trial liked using a contraceptive that also reduced the frequency of their menstrual periods. Cycle control was fairly good, and side effects, apart from weight gain and breast problems, were no commoner than those experienced on conventional oral contraceptive treatment. Our group of volunteers was not a random crosssection of the UK population, and it would be interesting to know how acceptable this regimen would be if made more widely available. Moreover, the clinic doctors and nurses were less enthusiastic than the participants about the advantages of reducing the number of menstrual periods.
A World Health Organisation survey of knowledgeable sources in 10 countries showed that "the unexpected presence or absence of vaginal bleeding, or variations in its characteristics, is alarming to women and perceived as a symptom of abnormality."4 There is evidence, however, from several other sources that women would welcome the opportunity to manipulate their menstrual patterns. Conventional oral contraceptives have often been used to delay menstruation for social reasons, for example-marriage, examinations, competitive sport-and continuous lynoestrenol treatment has been used in the management of the mentally retarded.5 Miller and Smith" interviewed a random cross-section of 88 unmarried, White, 18-23 year-old Californian girls, over half of whom were leading an active sex life, and found that 800o of them favoured the concept of eliminating menstruation. Clinical trials with long-acting injectable contraceptives that induce long-term amenorrhoea (400°, of women have amenorrhoea after three injections) have sometimes proved popular for this very reason.7 There are also cultural reasons why women in developing countries might welcome the opportunity to regulate menstrua-20 AUGUST 1977 tion. It is considered unclean by some Hindu women to prepare their husband's food during menstruation; a Moslem woman cannot pray in the mosque when menstruating-a particularly burdensome restraint during the annual feast of Ramadan. A preliminary trial of a "Ramadan pill" in Calcutta in 1976 showed that the concept was understood by poor urban women.8 A few Moslem women already use hormonal treatment to postpone the menses when on pilgrimage to Mecca. Some Buddhists think it is wrong to enter a temple during menstruation. Possibly some of the emerging middle classes of the Third World countries might like to change their menstrual patterns for reasons of social convenience as in the West; the cost of sanitary protection is relatively a much greater burden for a woman with limited income. Perhaps other social groups would also like to avail themselves of this opportunity on specific occasions.
Having established that infrequent periods are welcome and attainable, we must now define the optimal dosage of steroids necessary to maintain symptom-free cycles, and establish the most acceptable cycle length. The present tri-cycle regimen is certainly not the final solution to this problem. 
